Cargando…
Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
BACKGROUND: For programmed cell death protein 1/programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC), the addition of immune checkpoint inhibitors (ICIs) to chemotherapy has been shown to increase the objective response rate (ORR) by only 13.4–16.3%. Thus, examining conver...
Autores principales: | Tang, Jing, Ma, Xuqian, Chen, Xin, Feng, Mingqian, Jin, Xin, Wang, Ke, Wan, Jixi, Zhu, Xianmin, Xie, Rong, Dong, Shuang, Hu, Sheng, Jiang, Hui, Xie, Conghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372655/ https://www.ncbi.nlm.nih.gov/pubmed/35965796 http://dx.doi.org/10.21037/atm-22-3423 |
Ejemplares similares
-
A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
por: Feng, Yan, et al.
Publicado: (2022) -
An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers
por: Wang, Ninghai, et al.
Publicado: (2021) -
MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020) -
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020) -
Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
por: Dheilly, Elie, et al.
Publicado: (2018)